New RA drug LFD-200 enters first human safety trials
Disease control
Recruiting now
This early-phase study is testing a new drug called LFD-200 to see if it is safe and how the body processes it. The trial includes healthy adults and people with moderate to severe rheumatoid arthritis. Participants receive either the drug, a placebo, or an active comparator. The…
Phase: PHASE1 • Sponsor: Lifordi Immunotherapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC